Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice

Vascular Pharmacology

Volumn 79, Issue , 2016, Pages 16-23

  Salim, Hotimah Masdan ^a   Fukuda, Daiju ^a   Higashikuni, Yasutomi ^b   Tanaka, Kimie ^b   Hirata, Yoichiro ^c   Yagi, Shusuke ^a   Soeki, Takeshi ^a   Shimabukuro, Michio ^a   Sata, Masataka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

DPP 4 inhibitor; Endothelial function; GLP 1; Inflammation; Linagliptin; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; APOLIPOPROTEIN E; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; LINAGLIPTIN; PALMITIC ACID; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ACETYLCHOLINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL;

ABDOMINAL AORTA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; CELL INFILTRATION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASODILATATION; WILD TYPE; ANIMAL; ATHEROSCLEROSIS; BLOOD; C57BL MOUSE; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; KNOCKOUT MOUSE; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; THORACIC AORTA; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD GLUCOSE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LINAGLIPTIN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN CULTURE TECHNIQUES; VASODILATION;

EID: 84959161493     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.08.011     Document Type: Article

References (51)

1. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999, 340(2):115-126.
2. Hink U., Li H., Mollnau H., Oelze M., Matheis E., Hartmann M., Skatchkov M., Thaiss F., Stahl R.A., Warnholtz A., Meinertz T., Griendling K., Harrison D.G., Forstermann U., Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 2001, 88(2):E14-E22.
3. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109(23 Suppl. 1):III27-III32.
4. Drucker D.J. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013, 62(10):3316-3323.
5. Jialal I., Bajaj M. DPP-4 inhibitors and atherosclerosis: the promise. Atherosclerosis 2013, 227(2):224-225.
6. Matsubara J., Sugiyama S., Akiyama E., Iwashita S., Kurokawa H., Ohba K., Maeda H., Fujisue K., Yamamoto E., Kaikita K., Hokimoto S., Jinnouchi H., Ogawa H. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ. J. 2013, 77(5):1337-1344.
7. Murohara T. Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection. J. Am. Coll. Cardiol. 2012, 59(3):277-279.
8. Scheen A.J. Cardiovascular effects of gliptins. Nat. Rev. Cardiol. 2013, 10(2):73-84.
9. Ussher J.R., Drucker D.J. Cardiovascular actions of incretin-based therapies. Circ. Res. 2014, 114(11):1788-1803.
10. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117(18):2340-2350.
11. Nystrom T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 2004, 287(6):E1209-E1215.
12. Hirata Y., Kurobe H., Nishio C., Tanaka K., Fukuda D., Uematsu E., Nishimoto S., Soeki T., Harada N., Sakaue H., Kitagawa T., Shimabukuro M., Nakaya Y., Sata M. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury. Eur. J. Pharmacol. 2013, 699(1-3):106-111.
13. Ervinna N., Mita T., Yasunari E., Azuma K., Tanaka R., Fujimura S., Sukmawati D., Nomiyama T., Kanazawa A., Kawamori R., Fujitani Y., Watada H. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 2013, 154(3):1260-1270.
14. Shah Z., Kampfrath T., Deiuliis J.A., Zhong J., Pineda C., Ying Z., Xu X., Lu B., Moffatt-Bruce S., Durairaj R., Sun Q., Mihai G., Maiseyeu A., Rajagopalan S. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011, 124(21):2338-2349.
15. Terasaki M., Nagashima M., Nohtomi K., Kohashi K., Tomoyasu M., Sinmura K., Nogi Y., Katayama Y., Sato K., Itoh F., Watanabe T., Hirano T. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice. PLoS One 2013, 8(8):e70933.
16. Zeng Y., Li C., Guan M., Zheng Z., Li J., Xu W., Wang L., He F., Xue Y. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms. Cardiovasc. Diabetol. 2014, 13:32.
17. Doupis J. Linagliptin: from bench to bedside. Drug Des. Devel. Ther. 2014, 8:431-446.
18. Moghadasian M.H., Nguyen L.B., Shefer S., McManus B.M., Frohlich J.J. Histologic, hematologic, and biochemical characteristics of apo E-deficient mice: effects of dietary cholesterol and phytosterols. Lab. Invest. 1999, 79(3):355-364.
19. Fukuda D., Sata M., Ishizaka N., Nagai R. Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28(1):90-96.
20. Matsumoto S., Shimabukuro M., Fukuda D., Soeki T., Yamakawa K., Masuzaki H., Sata M. Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice. Cardiovasc. Diabetol. 2014, 13:30.
21. Chrysant S.G., Chrysant G.S. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am. J. Cardiol. 2012, 109(11):1681-1685.
22. Arakawa M., Mita T., Azuma K., Ebato C., Goto H., Nomiyama T., Fujitani Y., Hirose T., Kawamori R., Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59(4):1030-1037.
23. Dai Y., Wang X., Ding Z., Dai D., Mehta J.L. DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway. Acta Diabetol. 2014, 51(3):471-478.
24. Matheeussen V., Waumans Y., Martinet W., Van Goethem S., Van der Veken P., Scharpe S., Augustyns K., De Meyer G.R., De Meester I. Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. Basic Res. Cardiol. 2013, 108(3):350.
25. Vanhoutte P.M. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ. J. 2009, 73(4):595-601.
26. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 2003, 23(2):168-175.
27. Oeseburg H., de Boer R.A., Buikema H., van der Harst P., van Gilst W.H., Sillje H.H. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler. Thromb. Vasc. Biol. 2010, 30(7):1407-1414.
28. Oyama J., Higashi Y., Node K. Do incretins improve endothelial function?. Cardiovasc. Diabetol. 2014, 13:21.
29. Shah Z., Pineda C., Kampfrath T., Maiseyeu A., Ying Z., Racoma I., Deiuliis J., Xu X., Sun Q., Moffatt-Bruce S., Villamena F., Rajagopalan S. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vasc. Pharmacol. 2011, 55(1-3):2-9.
30. Nakamura K., Oe H., Kihara H., Shimada K., Fukuda S., Watanabe K., Takagi T., Yunoki K., Miyoshi T., Hirata K., Yoshikawa J., Ito H. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc. Diabetol. 2014, 13:110.
31. Saraiva F.K., Sposito A.C. Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc. Diabetol. 2014, 13(1):142.
32. Salheen S.M., Panchapakesan U., Pollock C.A., Woodman O.L. The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose. Pharmacol. Res. 2015, 94:26-33.
33. Ding L., Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol. Sin. 2012, 33(1):75-81.
34. Gaspari T., Liu H., Welungoda I., Hu Y., Widdop R.E., Knudsen L.B., Simpson R.W., Dear A.E. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab. Vasc. Dis. Res. 2011, 8(2):117-124.
35. Nakagami H., Pang Z., Shimosato T., Moritani T., Kurinami H., Koriyama H., Tenma A., Shimamura M., Morishita R. The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome. Hypertens. Res. 2014, 37(7):629-635.
36. Kroller-Schon S., Knorr M., Hausding M., Oelze M., Schuff A., Schell R., Sudowe S., Scholz A., Daub S., Karbach S., Kossmann S., Gori T., Wenzel P., Schulz E., Grabbe S., Klein T., Munzel T., Daiber A. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc. Res. 2012, 96(1):140-149.
37. Koibuchi N., Hasegawa Y., Katayama T., Toyama K., Uekawa K., Sueta D., Kusaka H., Ma M., Nakagawa T., Lin B., Kim-Mitsuyama S. DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovasc. Diabetol. 2014, 13:157.
38. Knopp R.H., Retzlaff B., Walden C., Fish B., Buck B., McCann B. One-year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in free-living subjects. Proc. Soc. Exp. Biol. Med. 2000, 225(3):191-199.
39. Sastre C., Rubio-Navarro A., Buendia I., Gomez-Guerrero C., Blanco J., Mas S., Egido J., Blanco-Colio L.M., Ortiz A., Moreno J.A. Hyperlipidemia-associated renal damage decreases Klotho expression in kidneys from ApoE knockout mice. PLoS One 2013, 8(12):e83713.
40. Kim F., Tysseling K.A., Rice J., Pham M., Haji L., Gallis B.M., Baas A.S., Paramsothy P., Giachelli C.M., Corson M.A., Raines E.W. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler. Thromb. Vasc. Biol. 2005, 25(5):989-994.
41. Lee C.H., Lee S.D., Ou H.C., Lai S.C., Cheng Y.J. Eicosapentaenoic acid protects against palmitic acid-induced endothelial dysfunction via activation of the AMPK/eNOS pathway. Int. J. Mol. Sci. 2014, 15(6):10334-10349.
42. Uruno A., Sugawara A., Kanatsuka H., Kagechika H., Saito A., Sato K., Kudo M., Takeuchi K., Ito S. Upregulation of nitric oxide production in vascular endothelial cells by all-trans retinoic acid through the phosphoinositide 3-kinase/Akt pathway. Circulation 2005, 112(5):727-736.
43. Chai W., Dong Z., Wang N., Wang W., Tao L., Cao W., Liu Z. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 2012, 61(4):888-896.
44. Erdogdu O., Nathanson D., Sjoholm A., Nystrom T., Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol. Cell. Endocrinol. 2010, 325(1-2):26-35.
45. Guzik T.J., Sadowski J., Guzik B., Jopek A., Kapelak B., Przybylowski P., Wierzbicki K., Korbut R., Harrison D.G., Channon K.M. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2006, 26(2):333-339.
46. Loffredo L., Martino F., Carnevale R., Pignatelli P., Catasca E., Perri L., Calabrese C.M., Palumbo M.M., Baratta F., Del Ben M., Angelico F., Violi F. Obesity and hypercholesterolemia are associated with NOx2 generated oxidative stress and arterial dysfunction. J. Pediatr. 2012, 161(6):1004-1009.
47. Haddad P., Dussault S., Groleau J., Turgeon J., Maingrette F., Rivard A. Nox2-derived reactive oxygen species contribute to hypercholesterolemia-induced inhibition of neovascularization: effects on endothelial progenitor cells and mature endothelial cells. Atherosclerosis 2011, 217(2):340-349.
48. Aroor A.R., Sowers J.R., Jia G., DeMarco V.G. Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol. 2014, 307(4):H477-H492.
49. Damas J.K., Waehre T., Yndestad A., Ueland T., Muller F., Eiken H.G., Holm A.M., Halvorsen B., Froland S.S., Gullestad L., Aukrust P. Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects. Circulation 2002, 106(1):36-42.
50. da Silva Junior W.S., de Godoy-Matos A.F., Kraemer-Aguiar L.G. Dipeptidyl peptidase 4: a new link between diabetes mellitus and atherosclerosis?. Biomed. Res. Int. 2015, 2015:816164.
51. Morishita R., Nakagami H. Teneligliptin: expectations for its pleiotropic action. Expert. Opin. Pharmacother. 2015, 16(3):417-426.